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Brief Definitive Report
Although tremendous progress has been made 
in identifying recurrent somatic mutations that 
drive acute myeloid leukemia (AML) patho-
genesis, many of these genetic lesions cause a 
loss of protein function and do not suggest clear 
therapeutic opportunities (Welch et al., 2012). 
Genetic screens have emerged as powerful ap-
proaches to identify vulnerabilities and thera-
peutic opportunities in cancer cells (Luo et al., 
2009; Zuber et al., 2011). In a recent in vivo 
shRNA screen (Miller et al., 2013) using pri-
mary mouse MLL-AF9 leukemia cells (Krivtsov 
et al., 2006; Somervaille and Cleary, 2006), we 
found that cells expressing Csnk1a1 shRNAs 
were powerfully depleted over time, indicating 
that Csnk1a1 is required for the survival of 
MLL-AF9 leukemia-propagating cells and may 
represent a novel therapeutic target for AML.
Csnk1a1, a serine-threonine kinase, is a cen-
tral regulator of multiple pathways that are crit-
ical for normal and malignant stem cell biology, 
including the  catenin and p53 pathways (Liu 
et al., 2002; Wang et al., 2010; Zhao et al., 2010; 
Elyada et al., 2011; Luis et al., 2011). More pre-
cisely, Csnk1a1 suppression increases  catenin 
and p53 activity (Liu et al., 2002; Chen et al., 
2005; Huart et al., 2009). Csnk1a1 plays a critical 
role in the biology of diffuse large B cell lym-
phoma by regulating NF-B signaling (Bidère 
et al., 2009), but the role of Csnk1a1 in leukemia 
has not been examined. We therefore sought to 
explore the role of Csnk1a1 in AML.
RESULTS AND DISCUSSION
In a previous pooled in vivo shRNA screen   
in primary mouse MLL-AF9 leukemia cells, 
Csnk1a1 scored at the top of our list of genes 
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Despite extensive insights into the underlying genetics and biology of acute myeloid leuke-
mia (AML), overall survival remains poor and new therapies are needed. We found that 
casein kinase 1  (Csnk1a1), a serine-threonine kinase, is essential for AML cell survival  
in vivo. Normal hematopoietic stem and progenitor cells (HSPCs) were relatively less affected 
by shRNA-mediated knockdown of Csnk1a1. To identify downstream mediators of Csnk1a1 
critical for leukemia cells, we performed an in vivo pooled shRNA screen and gene expression 
profiling. We found that Csnk1a1 knockdown results in decreased Rps6 phosphorylation, 
increased p53 activity, and myeloid differentiation. Consistent with these observations,  
p53-null leukemias were insensitive to Csnk1a1 knockdown. We further evaluated whether 
D4476, a casein kinase 1 inhibitor, would exhibit selective antileukemic effects. Treatment 
of leukemia stem cells (LSCs) with D4476 showed highly selective killing of LSCs over nor-
mal HSPCs. In summary, these findings demonstrate that Csnk1a1 inhibition causes 
reduced Rps6 phosphorylation and activation of p53, resulting in selective elimination of 
leukemia cells, revealing Csnk1a1 as a potential therapeutic target for the treatment of AML.
© 2014 Järås et al.  This article is distributed under the terms of an Attribution– 
Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first  six  months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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followed the percentage of GFP+ leukemia cells over time. 
Based on findings from three independent shRNAs target-
ing Csnk1a1, we found that leukemia cells with Csnk1a1 
knockdown were depleted 15- to 40-fold over a 2-wk period 
in both the spleen and BM, compared with cells expressing 
control shRNA (Fig. 1 C), without any defect in BM hom-
ing (Fig. 1 D).
To examine the effect of the same shRNAs on normal 
hematopoiesis,  we  expressed  the  Csnk1a1  shRNAs  in 
LinSca+Kit+ (LSK) hematopoietic stem and progenitor cells 
(HSPCs) and transplanted the cells into recipient mice. In con-
trast to the profound depletion observed in leukemia cells after 
that are essential for the leukemia cells, although this finding 
was not validated (Miller et al., 2013). We therefore first tested 
the knockdown efficiency and antileukemia efficacy of indi-
vidual Csnk1a1 shRNAs. We identified three distinct shRNAs 
that decreased the expression of Csnk1a1 mRNA and pro-
tein by >60% (Fig. 1, A and B). To examine whether Csnk1a1 
is  essential  for  primary  mouse  MLL-AF9  leukemia  cells   
in vivo, we used lentiviruses that coexpress individual shRNAs 
with GFP to transduce MLL-AF9 AML cells that were en-
riched for leukemia stem cells (LSCs) by sorting for c-Kithigh 
cells (Krivtsov et al., 2006). After transplantation of the   
leukemia cells into sublethally irradiated recipient mice, we   
Figure 1.  Silencing of Csnk1a1 selectively de-
pletes mouse leukemia cells in a kinase-dependent 
manner. (A) TaqMan-PCR was used to assess Csnk1a1 
transcript levels in Csnk1a1 shRNA 1–3 (Csnk1a1-sh1-3)–
expressing mouse leukemia cells. Csnk1a1 levels are 
presented as the percentage of transcript remaining 
relative to the luciferase control shRNA (Control-sh)–
expressing cells (n = 3). (B) Western blot demonstrating 
Csnk1a1 protein levels in shRNA-expressing leukemia 
cells together with Actin as endogenous control.  
(C) c-Kithigh dsRed+ leukemia cells were transduced with 
lentiviral vectors coexpressing GFP and shRNAs targeting 
Csnk1a1 and then transplanted via the tail vein into 
wild-type mice. The percentage of GFP+ cells within 
dsRed+ population was assessed before injection (input) 
and in mice BM and spleen 13 d after transplant. Data 
are presented as the GFP percentage normalized to the 
input measurement (three mice per group; each mouse 
was injected with leukemia cells from independent 
transductions). (D) BM homing experiment in which the 
percentage of GFP+ leukemia cells in the BM 24 h after 
transplantation was compared with corresponding  
in vitro cultured cells (five mice per group; each mouse 
was injected with leukemia cells from independent 
transductions). (E) After being transplanted with CD45.2 
LSK cells transduced with lentiviral vectors coexpressing 
GFP and shRNAs targeting Csnk1a1, recipient mice were 
assessed for the percentage of GFP+ cells within the 
CD45.2 population in the peripheral blood for 24 wk (at 
least five mice per group; each mouse injected with 
leukemia cells from independent transductions). The GFP 
percentage was normalized to the input measurement. 
(F) Csnk1a1 rescue experiment in which leukemia cells 
were transduced with both puromycin-resistant lenti-
viral shRNA vectors and retroviral vectors coexpressing 
GFP only (control), shRNA-resistant Csnk1a1 wild-type 
cDNA (Csnk1a1), or a kinase-dead Csnk1a1 cDNA 
(Csnk1a1(D136N)). Csnk1a1 rescue is presented as the 
ratio between the percentage of GFP-positive cells 
within Csnk1a1-sh1– versus Control-sh–expressing cells 
at day 6 after lentiviral transduction. (G) 100,000 sorted 
GFP+ leukemia cells carrying shRNAs were transplanted 
into wild-type recipient mice. Survival of the mice is 
shown in Kaplan–Meier curves (at least six mice per 
group; each mouse was injected with leukemia cells 
from independent transductions). Means and SD are 
shown (*, P < 0.05; **, P < 0.01; ***, P < 0.001).JEM Vol. 211, No. 4  607
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express GFP, and therefore Csnk1a1 or control shRNAs ex-
pressed from the same lentiviral vector, were purified and trans-
planted into recipient mice. Mice injected with leukemia cells 
expressing Csnk1a1 shRNAs lived significantly longer than 
control mice (Fig. 1 G). In aggregate, these data demonstrate 
that the MLL-AF9 leukemia cells are dependent on Csnk1a1 
kinase function for growth and survival.
To determine the molecular mechanisms underlying the 
critical role of Csnk1a1 in leukemia, we performed an in vivo 
pooled shRNA screen on genes implicated as direct or indirect 
downstream targets of Csnk1a1 signaling. In this screen, 28 genes 
targeted by 149 shRNAs and 8 control shRNAs lacking endog-
enous target sequences were included (Table S1). The top hit in 
this screen was ribosomal protein S6 (Rps6; Fig. 2 A). Suppression 
of Rps6 with three independent shRNAs resulted in a dramatic 
depletion of leukemia cells in both spleen and BM over a 2-wk 
period (Fig. 2 B). All three hairpins targeting Rps6 showed 
successful knockdown of the Rps6 transcript (Fig. 2 C).
RPS6 activity is regulated by phosphorylation by CSNK1A1, 
which phosphorylates serine residue 247, enhancing the phos-
phorylation of upstream sites (Hutchinson et al., 2011), as well 
as by the ribosomal S6 kinases 1 and 2 (Magnuson et al., 2012). 
just 2 wk, normal HSPCs expressing Csnk1a1 shRNAs were 
only depleted three- to fourfold over 24 wk in a long-term re-
constitution assay. These findings demonstrate that Csnk1a1 
shRNAs preferentially deplete leukemia cells (Fig. 1 E).
To address the possibility that our results were caused by 
off-target effects of the shRNAs, we generated an shRNA-
resistant Csnk1a1 cDNA in which multiple silent mutations 
were introduced at the shRNA-binding sites. Coexpression 
of this shRNA-resistant cDNA successfully rescued the deple-
tion of leukemia cells expressing Csnk1a1 shRNAs (Fig. 1 F).
Because inhibition of kinase activity is the most straight-
forward way to target Csnk1a1 pharmacologically, we tested 
whether the kinase function of Csnk1a1 is essential for leuke-
mia cells. We introduced a known mutation that inactivates 
the kinase domain (Csnk1a1(D136N); Peters et al., 1999; 
Davidson et al., 2005; Bidère et al., 2009) into the shRNA-
resistant Csnk1a1 cDNA. We found that the kinase-dead cDNA 
did not rescue the effect of the Csnk1a1 shRNAs, demonstrat-
ing that Csnk1a1 kinase function is essential for leukemia 
cells (Fig. 1 F).
We next examined whether suppression of Csnk1a1 could 
increase the survival of leukemic mice. Leukemia cells that 
Figure 2.  Csnk1a1 suppression leads to dramatic reduction in Rps6 phosphorylation. (A) Genes targeted by two or more shRNAs that depleted 
leukemia cells >40-fold in the BM and spleen (n = 5). (B) Graphs showing fold change of all shRNAs included in the screen. Rps6 was identified as a 
strong hit with three separate shRNAs (Rps6-sh1–3) all depleting leukemia cells >40-fold in the BM and spleen after 14 d in vivo relative to input (same 
experiment as in A). Dashed lines depict 40-fold depletion. (C) TaqMan-PCR was used to assess Rps6 transcript levels in shRNA-expressing leukemia cells. 
Rps6 levels are presented as the percentage of transcript remaining relative to Control-sh–expressing cells (n = 3). (D) Western blot demonstrating Rps6 
protein levels and Rps6 phosphorylation in shRNA-expressing mouse leukemia cells together with Actin as endogenous control. (E) Rps6 rescue experi-
ment in which leukemia cells were transduced with both puromycin-resistant lentiviral shRNA vectors and retroviral vectors coexpressing GFP only (Con-
trol), Rps6 cDNA, or a Rps6-S5D (phosphomimetic mutant) cDNA (n = 3). Rps6 rescue is presented as the ratio between the percentage of GFP-positive 
cells within Csnk1a1-sh1 versus Control-sh–expressing cells. Means and SD are shown (*, P < 0.05).608 Csnk1a1 is a therapeutic target in AML | Järås et al.
Figure 3.  Csnk1a1 suppression activates a p53 response. (A) In leukemia cells with shRNA-mediated suppression of Csnk1a1, p53 signatures are 
enriched by GSEA. (B) Western blot demonstrating induced p53 and p21 expression after shRNA-mediated silencing of Csnk1a1 in leukemia cells. Actin 
was used as an endogenous control. (C) In leukemia cells with Csnk1a1 suppressed, up-regulated genes were enriched in a myeloid differentiation signa-
ture (left), and down-regulated genes were enriched in a hematopoietic stem cell (HSC) versus GMP down signature, i.e., a signature of genes down-regulated 
in GMPs relative to HSCs. (D) Histogram depicting c-Kit expression 72 h after transductions with shRNA-expressing lentiviral vectors. (E) MLL-AF9 JEM Vol. 211, No. 4  609
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increased expression of a p53 signature (Fig. 3 A; Kanehisa et al., 
2012). Western blot analysis confirmed increased p53 and p21 
expression (Fig. 3 B). In addition, we found that knockdown 
of Csnk1a1 caused changes in gene expression enriched in 
myeloid cell differentiation signatures (Fig. 3 C; Krivtsov et al., 
2006; Hahn et al., 2009). Consistent with this result, we found 
decreased c-Kit expression on the surface of leukemia cells ex-
pressing Csnk1a1 shRNAs (Fig. 3 D).
Because decreased Rps6 phosphorylation causes activation 
of p53 (Khalaileh et al., 2013) and Csnk1a1 may also regulate 
p53 through other mechanisms, we hypothesized that p53 is a 
We therefore tested whether shRNA-mediated suppression of 
Csnk1a1 affects the phosphorylation of Rps6 in leukemia cells. 
Total Rps6 protein levels were not changed after Csnk1a1 sup-
pression, but Rps6 phosphorylation was powerfully decreased in 
leukemia cells (Fig. 2 D). Overexpression of a phosphomi-
metic mutant Rps6 cDNA (Rps6S5D) that activates Rps6 par-
tially rescued the proliferative defect induced by Csnk1a1 
knockdown (Fig. 2 E).
To obtain further insight into the molecular consequences 
of Csnk1a1 suppression in leukemia, we performed gene expres-
sion profiling. We found that Csnk1a1 knockdown significantly 
leukemia cells in Tp53/ and Tp53+/+ background were transduced with vectors coexpressing GFP and Control-sh or Csnk1a1-sh1. The GFP percentage 
was measured 2 (input) and 7 d after transduction. Data are presented as the GFP percentage normalized to the input measurement (n = 3). (F) 200,000 
sorted GFP+ Tp53/ leukemia cells carrying Control-sh or Csnk1a1-sh1 were transplanted into wild-type recipient mice. Survival of the mice is shown in 
Kaplan–Meier curves (six mice per group; each mouse was injected with leukemia cells from independent transductions). (G) Leukemia cells carrying shRNAs 
were analyzed for early (Annexin V+ Hoechst 33342) and late (Annexin V+ Hoechst 33342+) apoptotic cells (n = 3). (H) Cell cycle analysis on leukemia 
cells carrying shRNAs (n = 3). Means and SD are shown (**, P < 0.01 ***, P < 0.001;).
 
Figure 4.  Small molecule inhibition of Csnk1a1 
selectively kills leukemia cells. (A) Normal LSK, 
Tp53/, and Tp53+/+ c-Kithigh leukemia cells were 
treated in medium supplemented with increasing 
doses of D4476, and cell number was assessed after  
4 d. Data are presented as the cell count normalized to 
the DMSO control (n = 3). Black asterisks depict sig-
nificance between Tp53+/+ leukemia and Tp53/ 
leukemia comparison, and red asterisks depict signifi-
cance between LSK and Tp53+/+ leukemia cell com-
parison. (B) c-Kithigh leukemia cells were transduced 
with vectors coexpressing shRNAs and GFP and then 
treated with D4476 for 4 d. Data are presented as the 
percentage of GFP+ cells after treatment normalized 
to the DMSO control (n = 3). (C) c-Kithigh leukemia 
cells were transduced with a vector coexpressing 
Csnk1a1 and GFP and then treated with D4476 for 4 d. 
Data are presented as the percentage of GFP+ cells 
after treatment normalized to the DMSO control  
(n = 3). (D) 10,000 LSK cells (CD45.1+) and 10,000  
c-Kithigh leukemia cells (dsRed+) were co-cultured on 
GFP-positive mouse mesenchymal stroma cells for  
48 h in the presence of 40 µM D4476 (6 mice; each 
mouse was injected with cells from independent drug 
treatments) or DMSO control (10 mice; each mouse 
was injected with cells from independent drug treat-
ments) and then transplanted into CD45.2+ recipients 
along with CD45.1+CD45.2+ competitor cells. The 
green line depicts the group with LSK-treated cells 
only, i.e., no leukemia cells were added to the wells 
(four mice; each mouse was injected with cells from 
independent drug treatments). Survival is shown in 
Kaplan–Meier curves. (E) Repopulation of donor cells 
in peripheral blood was determined as the percentage 
of donor (CD45.1+CD45.2) cells among the donor 
and competitor cells after subtracting the leukemia 
(dsRed+) cell population (same experiment as in D). The green line depicts the group with LSK-treated cells only, and the blue line depicts the group with 
D4476-treated mixed c-Kithigh leukemia and LSK cells. Flow cytometric analysis was performed at 4, 8, and 16 wk. (F) M9 leukemia cells and cord blood 
(CB) CD34+ cells were cultured in medium supplemented with increasing doses of D4476, and cell number was assessed after 4 d. Data are presented as 
the cell count normalized to DMSO control (n = 3). Means and SD are shown (*, P < 0.05; **, P < 0.01; ***, P < 0.001).610 Csnk1a1 is a therapeutic target in AML | Järås et al.
expression of  catenin, downstream of Csnk1a1 inhibition, 
has also been shown to induce p53 (Damalas et al., 2001), and 
Csnk1a1 can regulate p53 by binding to MDM2 (Huart et al., 
2009). Our findings suggest that targeting of Csnk1a1 pro-
vides a potential approach to the therapeutic activation of p53 
in AML, a disorder predominantly associated with nonmutated 
Tp53 (Patel et al., 2012).
MATERIALS AND METHODS
Leukemia model. All animal experiments were conducted with an Institu-
tional Animal Care and Use Committee–approved protocol. Mouse MLL-AF9 
leukemias in a dsRed transgenic background (6051; The Jackson Laboratory) 
were generated as previously described (Miller et al., 2013). To enrich for 
LSCs, femurs and tibias from leukemic mice were first harvested, crushed, 
and filtered, and red blood cells were lysed using lysis buffer (BD). Then BM 
cells were stained with APC-conjugated anti–c-Kit (clone 2B8; eBioscience) 
and dsRed+c-Kithigh cells (20% high) were sorted (FACSAria II; BD). MLL-
AF9–driven Tp53/ leukemias were generated from c-Kit–enriched BM 
cells from Tp53/ mice (002101; The Jackson Laboratory).
Cell  cultures  and  transductions. Sorted c-Kithigh leukemia cells were 
plated in RPMI-1640 (Sigma-Aldrich) medium supplemented with 1% 
l-glutamine, 1% penicillin and streptomycin, and 10% fetal bovine serum (Invit-
rogen) in 10 ng/ml mouse IL-3 (mIL-3; PeproTech). For isolation of LSK cells, 
c-Kit–positive cells were first isolated using MACS beads (Miltenyi Biotec), 
followed by antibody staining and sorting for lineagelow, Sca-1+, and c-Kit+ 
cells. For transductions of leukemia cells, the medium was also supplemented 
with 10 ng/ml mIL-6, 20 ng/ml mouse stem cell factor (mSCF), and 5 µg/ml 
polybrene (Sigma-Aldrich). Virus-containing medium was mixed with cells, 
and spinfection was performed at 2,500 rpm for 90 min at 37°C. Lentiviral 
vectors were pseudotyped with  VSV-G envelope, whereas oncoretroviral vec-
tors were pseudotyped with ecotropic envelope and produced using standard 
protocols. For LSK cells, sorted cells were put in StemSpan Serum-Free   
Expansion Medium (STEMCELL Technologies) supplemented with 100 ng/ml 
mouse thrombopoietin (mTpo; PeproTech) and 100 ng/ml mSCF (Pepro-
Tech). LSK cells were prestimulated for 24 h and transduced using spinocula-
tion as described above. In the Csnk1a1 and Rps6 rescue experiments, leukemia 
cells were first transduced with the retroviral MIG vectors and then after 24 h 
subjected to an additional transduction with lentiviral vectors expressing 
shRNAs, and then 24 h later, puromycin was added to the medium at 0.5 µg/ml. 
M9 cells were cultured in alfa Mem (Life Technologies) medium supple-
mented with 10% human plasma (Sigma-Aldrich), 20% FBS, 1% l-glutamine, 
1% penicillin and streptomycin, 100 ng/ml SCF (PeproTech), 10 ng/ml IL-3 
(PeproTech), 5 ng/ml IL-7 (PeproTech), 5 ng/ml Flt3L (PeproTech), 50 µg/ml 
Gentamicin (Life Technologies), and 1 µg/ml heparin (Sigma-Aldrich).
Drug treatment using D4476. For inhibition of Csnk1a1, the small mole-
cule D4476 (Tocris Bioscience) was used. D4476 was added to leukemia cells 
cultured in 96-well plates (5,000 cells per well) in medium supplemented with 
10 ng/ml mIL-3. A D4476 dose titration was performed by adding 2.5 µM, 
5 µM, 10 µM, 20 µM, and 40 µM D4476 to cell cultures in a final DMSO 
percentage of 0.4%. Similarly, D4476 was added to LSK cells cultured in 
SFEM medium supplemented with mTpo and mScf. The number of cells after 
96 h of treatment was assessed with CountBright absolute counting beads 
(Invitrogen) using flow cytometry.
Microarray analysis. Global gene expression profiling of c-Kithigh leukemia 
cells was performed on sorted GFP+ cells, harvested 72 h after transduction 
with lentiviral vectors coexpressing shRNAs and GFP. RNA was extracted 
using TRIzol (Invitrogen), and samples were analyzed using Mouse WG-6 
version 2.0 Expression BeadChip (Illumina). Enrichment of gene expres-
sion signatures was analyzed using Gene Set Enrichment Analysis (GSEA; 
Subramanian et al., 2005). Raw data and normalized gene expression data 
critical mediator of the effects of Csnk1a1 suppression in leu-
kemia. To test this hypothesis, we generated MLL-AF9 leuke-
mia in a Tp53/ background.  We found that Tp53/ leukemia 
cells were resistant to the effects of Csnk1a1 silencing, both   
in vitro and in vivo (Fig. 3, E and F). These findings demonstrate 
that p53 function is essential for the antileukemic effects of 
Csnk1a1 knockdown. Consistent with p53 activation, Csnk1a1 
knockdown induced apoptosis and cell cycle arrest (Fig. 3,   
G and H; and Figs. S1 and S2).
To explore the potential therapeutic efficacy of targeting 
Csnk1a1, we tested whether D4476, a selective small molecule 
inhibitor of casein kinase 1 (Rena et al., 2004; Anastassiadis et al., 
2011), would exhibit antileukemic effects. Treatment of primary 
c-Kithigh leukemia cells in vitro with D4476 killed the leukemia 
cells with an EC50 of 6.5 µM, whereas concentrations up to 
40 µM had minimal effects on normal HSPCs and Tp53/ 
leukemia cells under similar culture conditions (Fig. 4 A).
To address whether D4476 killed c-Kithigh leukemia cells 
by inhibiting Csnk1a1, we decreased expression of Csnk1a1 
using shRNAs and demonstrated that these cells were sensi-
tized to D4476 in a dose-dependent manner (Fig. 4 B). Con-
versely, overexpression of Csnk1a1 decreased the sensitivity of 
leukemia cells to D4476 treatment, indicating that D4476 kills 
leukemia cells via on-target inhibition of Csnk1a1 (Fig. 4 C).
To examine the effect of D4476 on normal and malignant 
stem cells, we mixed 10,000 LSK cells with 10,000 c-Kithigh 
leukemia cells and treated them together, ex vivo, with D4476 
for 48 h and then injected the cells into lethally irradiated 
recipient mice. We found that the mice receiving DMSO 
control–treated cells died rapidly from aggressive leukemia. In 
contrast, mice receiving D4476-treated cells survived signifi-
cantly longer, and one third of these mice remained disease 
free for the 16-wk duration of the experiment (Fig. 4 D). Ad-
ditionally, the normal HSPCs were unaffected by the inhibi-
tor and thus contributed robustly to donor cell chimerism, 
indicating a selective toxicity toward the LSCs over the nor-
mal HSPCs (Fig. 4 E).
We next validated that CSNK1A1 is essential for human 
leukemia cells. Using MLL-ENL–transformed cord blood cells, 
M9 cells (Barabé et al., 2007), we found that expression of 
CSNK1A1 shRNAs successfully decreased CSNK1A1 expres-
sion and caused rapid depletion of leukemia cells (not depicted). 
In agreement with the mouse data, M9 cells were sensitive to 
D4476, whereas human cord blood CD34+ cells were insensi-
tive to treatment (Fig. 4 F).
Our experiments suggest that Csnk1a1 is essential for 
mouse and human AML cells and that the Csnk1a1 depen-
dence requires the Csnk1a1 kinase domain. Partial depletion 
of Csnk1a1 activity via shRNA knockdown or small mole-
cule inhibition resulted in a pronounced therapeutic window 
with a selective loss of the leukemia population. Consistent 
with previous studies linking Csnk1a1 to suppression of p53 
(Chen et al., 2005; Huart et al., 2009; Elyada et al., 2011), we 
found that lack of Rps6 phosphorylation and induction of 
p53 is a major consequence of Csnk1a1 loss in leukemia cells 
leading to enforced cell differentiation. In addition, increased JEM Vol. 211, No. 4  611
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10 min and washed before resuspension in 500 µl PBS. Cells were analyzed 
using the FACS LSRII.
Apoptosis. Leukemic GMPs were transduced with Control-sh or Csnk1a1-sh1, 
harvested 72 h later, and washed in PBS. Cells were then washed in 1× 
binding buffer (BD) and stained in 1× binding buffer in the presence of 
Annexin V–directly conjugated primary antibody for 20 min at room tem-
perature (Annexin V–APC; BD). After another washing step, cells were stained 
with Hoechst 33342 according to the manufacturer’s instructions and resus-
pended in flow buffer. Cells were subsequently analyzed using the FACS LSRII.
Homing  experiment. Leukemia cells were transduced with Control-sh, 
Csnk1a1-sh1, or Csnk1a1-sh2 coexpressing GFP and transplanted into suble-
thally irradiated mice 48 h after transduction. 24 h after transplantations, BM cells 
were harvested, and the percentage of GFP+ cells was determined using flow 
cytometric analysis within the dsRed+ cells. The percentage of GFP+ cells in 
corresponding in vitro cultured cells was measured 72 h after transduction.
Statistical analysis. Kaplan–Meier curves were generated using Prism 5 soft-
ware (GraphPad Software). In all figures, the mean values and SDs are shown. 
P-values were calculated using the Student’s t test or the Mantel–Cox (for 
Kaplan–Meier curves only) test. Significance is depicted with asterisks:   
*, P < 0.05; **, P < 0.01; ***, P < 0.001. For further details, see correspond-
ing figure legends.
Ex vivo drug treatment of leukemia and LSK cells on mesenchymal 
stroma. LSK cells and c-Kithigh leukemia cells were mixed and added onto 
BM mesenchymal stromal cells (BMSCs) derived from actin-GFP mice 
(000329; The Jackson Laboratory). The mesenchymal stroma cells were pre-
pared by plating RBC-lysed, freshly isolated BM cells in BMSC medium 
(400 ml -MEM [STEMCELL Technologies], 20% FBS [HyClone], and 5 ml 
Pen-Strep [CellGro]). Cells were grown in flasks in a 33°C/5% CO2 incuba-
tor for 10–17 d and split by brief trypsinization (0.25%; CellGro), filtered 
through a 70-µm filter, and grown another 3–4 d until nearly confluent. The 
cells were then trypsinized, filtered, and washed, and CD105+ cells were isolated 
with biotin-conjugated anti–mouse CD105 antibody (eBioscience) and Dy-
nabead M-280 streptavidin-linked magnetic beads (Invitrogen). The CD105+ 
cell fraction was replated for 2–3 d before being used for short-term experi-
mentation as described above. After 48 h of D4476 treatment, wells were trypsin-
ized and cells were washed before being injected to lethally irradiated CD45.2+ 
mice together with 1.5 × 106 freshly isolated CD45.1+CD45.2+ splenocytes.
Online supplemental material. Fig. S1 shows the gating strategy for 
Fig. 3 G. Fig. S2 shows the gating strategy for Fig. 3 H. Table S1 is a gene list 
showing the number of shRNAs that depleted leukemia cells >40-fold in 
BM and spleen. Online supplemental material is available at http://www 
.jem.org/cgi/content/full/jem.20131033/DC1.
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